Arican, OzerOnver, Nese2024-06-122024-06-1220111307-76351308-5255https://doi.org/10.5152/tdd.2011.06https://hdl.handle.net/20.500.14551/19681Cetuximab is a new monoclonal antibody against the epidermal growth factor receptor (EGFR). It has been shown that it is effective against multiple malignancies, including metastatic colorectal carcinoma. EGFR-inhibitors often cause mucocutaneous side effects, most commonly acneiform eruption. Acneiform eruption usually appears suddenly within the first two weeks of the treatment. The incidence and degree of eruption positively correlate with increasing doses and duration of the treatment with EGFR-inhibitors. Here, we report a case of severe acneiform eruption due to cetuximab in a 50-year-old female patient with colorectal cancer with multiple pulmonary and liver metastases.tr10.5152/tdd.2011.06info:eu-repo/semantics/openAccessCetuximabAcneiform EruptionAdverse EffectTherapyArticle512932N/AWOS:0004208687000072-s2.0-79955592325Q4